Peixe Rosa — Life Sciences & Translational Medicine
MONGUERA
Cancer Microbiome & Treatment Protocols
Monguera is a biotechnology and translational medicine opportunity focused on the relationship between tumor-associated bacteria, cancer progression and treatment response.
Its scientific approach investigates how bacterial interactions within the tumor environment may be addressed through carefully developed treatment protocols, including the potential use of existing approved medicines.
The objective is to develop clinically validated protocols that may improve treatment outcomes while establishing a commercially scalable model for their adoption.
Monguera's principal focus is the development and commercialization of treatment protocols and associated intellectual assets, rather than the discovery of entirely new pharmaceutical compounds.
MONGUERA — US$12 Million Co-Investment Opportunity
The Commercial Opportunity
Monguera is positioned to develop a differentiated oncology business around treatment protocols, scientific know-how, clinical methodologies and appropriately protected commercial rights.
Its proposed business model includes licensing validated protocols, strategic partnerships with qualified healthcare institutions and collaboration with pharmaceutical and clinical organizations.
The use of existing medicines may reduce certain development requirements associated with new-drug discovery, while clinical validation, safety, regulatory and commercial requirements remain applicable.
Commercial implementation depends on successful independent validation, appropriate regulatory pathways and enforceable commercial rights.
Development & Validation
Monguera builds upon an extended history of scientific investigation and treatment-protocol development.
The opportunity has undergone sufficient scientific and commercial assessment by Of Joseph PB&T to be selected for external co-investment.
Its next development stage emphasizes independent third-party scientific and clinical validation, supported by the Peixe Rosa translational medicine ecosystem.
This work is intended to establish the clinical evidence, reproducibility, regulatory basis and commercial credibility necessary for broader adoption.
The underlying scientific foundation and prior development are distinct from clinical outcomes that remain to be independently established.
Purpose-Built Enterprise
New company. Established foundations.
Monguera is being prepared for establishment as an independent operating enterprise with a clearly defined business purpose, appropriate capitalization, transparent governance and strategically selected management.
Of Joseph PB&T will arrange the contribution, transfer or licensing of the applicable developed assets, intellectual property, technology, know-how and commercial rights required for the new company's independent business objectives.
These arrangements will be established through appropriate legal documentation, subject to verified ownership and applicable institutional or third-party rights.
The new enterprise is designed to begin operations with clearly defined assets, responsibilities and obligations, avoiding unrelated historical liabilities and operational baggage through appropriate due diligence and transaction structuring.
Management will be selected strategically from a global pool of qualified scientific, technical, operational and commercial professionals according to the enterprise's specific requirements.
The Peixe Rosa Advantage
Monguera benefits from its development within the Peixe Rosa translational medicine ecosystem.
Peixe Rosa provides an institutional framework through which scientific, clinical and technical environments can support continued validation, translational research and enterprise development, subject to applicable cooperation arrangements.
Of Joseph PB&T's established Brazilian operations contribute institutional access, scientific and technical development capabilities and meaningful operating cost advantages.
These advantages are combined with internationally oriented scientific standards, regulatory pathways and commercial strategies.
The objective is to establish an independent, internationally credible oncology enterprise capable of developing commercial relationships and pursuing opportunities in global healthcare markets.
Capital Requirements
US$12 MILLION
Initial Co-Investment Capitalization
The proposed initial capitalization supports the establishment of Monguera as an independent operating enterprise and the execution of its next development milestones.
- Corporate formation, governance and initial operating capabilities.
- Appropriate asset contribution, transfer or licensing arrangements.
- Scientific and clinical validation.
- Regulatory preparation and intellectual-property protection.
- Strategic management and commercial development.
- Operating requirements and appropriate reserves.
Detailed participation terms are provided privately to qualified investors.
Enterprise Value Creation
Monguera's investment proposition reflects the value created through prior discovery, scientific development, technical know-how, intellectual assets, historical sponsor investment and accumulated commercial work.
Of Joseph PB&T's development and stewardship precede external co-investment and form part of the enterprise's investment valuation premise.
The next stage of value creation is centered on independent scientific and clinical validation, appropriate commercial-rights protection, regulatory advancement, institutional partnerships and the development of operating revenue.
Detailed participation terms are provided privately to qualified investors.
Commercial Development & Monetization
Independent Validation → Clinical Translation → Regulatory Authorization Where Required → Commercial Licensing & Partnerships → Operating Revenue → Potential Strategic Transactions or Investor Liquidity
The enterprise intends to commercialize validated treatment protocols and associated know-how through appropriate licensing and commercial relationships with qualified oncology and healthcare institutions.
Commercial timelines, licensing opportunities and potential liquidity events depend on the achievement of scientific, regulatory, operational and commercial milestones.